Zhuhai Hengqin Walvax, a private equity (PE) fund has officially registered at Asset Management Association of China (AMAC). This is the third private equity asset allocation funds of Jinsheng Capital and the sixth in China. Jinsheng became one of the first three and the only five private equity allocation fund managers in the country.
Genemind Biosciences has obtained tens of millions of yuan in A+ round of financing from Jinsheng Capital and other institutions. According to Genemind Biosciences, proceeds of this round of financing will be mainly used to promote the clinical application of its third-generation gene sequencing platform GenoCare.